Related posts

Top Covid-19 Vaccine Stocks to Bet on the Immunization Race (Updated)Top Biotech and Pharma Stocks to Bet on Cancer Cure & Control
Investor Insights

This summary was created by AI, based on 5 opinions in the last 12 months.

Experts are divided in their opinions regarding GlaxoSmithKline PLC. Some believe that the current share price is fairly valued and the company has a strong vaccine business, while others feel that there are better investment opportunities elsewhere. The company is under pressure with slow growth and cost-cutting, but has a good dividend yield and strong cashflow. The key concern is the company's drug pipeline, which may require acquisitions to strengthen. Overall, there is uncertainty about the company's future direction and use of capital.

Consensus
Mixed
Valuation
Fair Value
BUY ON WEAKNESS
GlaxoSmithKline PLC

Buy drug stocks when there's no good news about their drug pipelines, or else you pay up when there is good news, in which case it becomes a trade, not investment.

biotechnology / pharmaceutical
HOLD
GlaxoSmithKline PLC

Vaccine discoveries good for business.
Does not own shares at this time.
Market for pharmaceuticals separating between strong and weak players.
Current share price fairly valued.


biotechnology / pharmaceutical
SELL
GlaxoSmithKline PLC

Big pharmas are all under pressure, growth is hard to come by and so they're cost-cutting. All have lots of free cashflow and reasonable dividend yields. He prefers JNJ. 

biotechnology / pharmaceutical
DON'T BUY
GlaxoSmithKline PLC

Good business, but better opportunities out there.
Attractive dividend yield.
Not investing in business at this time.
Hard to evaluate R&D pipeline.
Would look elsewhere. 

biotechnology / pharmaceutical
COMMENT
GlaxoSmithKline PLC

They sold their personal care business to generate a lot of capital. They're strong in vaccines, but don't have a strong pipeline of drugs. So, they need to buy other companies to make up for that. Not a high PE and pays a good dividend. The key is what they will do with their capital.

biotechnology / pharmaceutical
RISKY
GlaxoSmithKline PLC

Great dividend yield of 6.3%, trades at only 10x earnings. Cheap, you can own it here. Grew vaccine business. New CEO shed some divisions, so now more of a pure pharma company, which has risks. Have to worry about pipeline constantly. JNJ, for example, is more diversified, and that's what he prefers.

biotechnology / pharmaceutical
DON'T BUY
GlaxoSmithKline PLC

It's been successfully recently, but they have to pay for their drug pipeline which looks reasonable. Not cheap, but no drug is coming to market that will do very well. So-so overall. There are better peers.

biotechnology / pharmaceutical
PAST TOP PICK
GlaxoSmithKline PLC
(A Top Pick Mar 04/20, Down 9%)

Still likes it. They spun off over-the counter and consumer pharmaceuticals like Advil and that's when shares dipped (last fall). He chose it back then to bet on Covid vaccines, but that didn't pan out. But he likes it for that spin off and you get paid a reasonable dividend.

biotechnology / pharmaceutical
DON'T BUY
GlaxoSmithKline PLC
Not expensive, 10x earnings. Be careful with pharma, look at the pipeline. Focusing on one area, and that's the risk. Volatility as drugs come off patent. Lots of restructuring. He owns JNJ instead with its 3 businesses. Yield over 5%.
biotechnology / pharmaceutical
Unspecified
GlaxoSmithKline PLC
It has re-structured and is selling off some of its personal care business, thereby concentrating more on the pharmaceutical side. Not expensive and has a dividend yield over 6%.
biotechnology / pharmaceutical
BUY
GlaxoSmithKline PLC
They're spinning off their consumer products division, so GSK has historically traded at a discount with slower growth than other drugmakers. New management has turned around the pharmaceuticals side and make good consumer products. Aging populations in the west is a tailwind.
biotechnology / pharmaceutical
DON'T BUY
GlaxoSmithKline PLC
Large pharmaceutical company. Business model challenging since large investment required to produce new products. Good company, but owns other names in the space.
biotechnology / pharmaceutical
BUY
GlaxoSmithKline PLC
Options trading He jumped on some options. He likes healthcare and is adding to the sector. he doing call buying with Glaxo, not stock buying. There's a lot of activity here.
biotechnology / pharmaceutical
BUY
GlaxoSmithKline PLC
In 2018, they planned to merge their consumer health business with Pfizer's consumer to create a powerhouse, and planned to spin off this unit in three years. Last summer they offered an update--everyone expects a big cut to their 5% dividend yield, but cut it by only 31%. Management also offered encouraging sales projections. A hedge fund wants to bring in new leadership; he's unsure of this, but these types of move tend to prod management to deliver for shareholders, which is another reason to like this. He sees 10% upside.
biotechnology / pharmaceutical
BUY
GlaxoSmithKline PLC
Pays a 5% yield. It's doing okay. Okay to own for income.
biotechnology / pharmaceutical
Showing 1 to 15 of 100 entries

GlaxoSmithKline PLC(GSK-N) Rating

Ranking : 3 out of 5

Bullish - Buy Signals / Votes : 1

Neutral - Hold Signals / Votes : 1

Bearish - Sell Signals / Votes : 2

Total Signals / Votes : 4

Stockchase rating for GlaxoSmithKline PLC is calculated according to the stock experts' signals. A high score means experts mostly recommend to buy the stock while a low score means experts mostly recommend to sell the stock.

GlaxoSmithKline PLC(GSK-N) Frequently Asked Questions

What is GlaxoSmithKline PLC stock symbol?

GlaxoSmithKline PLC is a American stock, trading under the symbol GSK-N on the New York Stock Exchange (GSK). It is usually referred to as NYSE:GSK or GSK-N

Is GlaxoSmithKline PLC a buy or a sell?

In the last year, 4 stock analysts published opinions about GSK-N. 1 analyst recommended to BUY the stock. 2 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for GlaxoSmithKline PLC.

Is GlaxoSmithKline PLC a good investment or a top pick?

GlaxoSmithKline PLC was recommended as a Top Pick by on . Read the latest stock experts ratings for GlaxoSmithKline PLC.

Why is GlaxoSmithKline PLC stock dropping?

Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.

Is GlaxoSmithKline PLC worth watching?

4 stock analysts on Stockchase covered GlaxoSmithKline PLC In the last year. It is a trending stock that is worth watching.

What is GlaxoSmithKline PLC stock price?

On 2024-06-21, GlaxoSmithKline PLC (GSK-N) stock closed at a price of $40.48.